and ciprofloxacin both increase QTc interval. Use Caution/Monitor.citalopramcitalopram increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Although citalopram is a weak inhibitor of 2D6, the potential for an interaction exists.atomoxetine and citalopram both increase QTc interval. Use Caution/Monitor.clomipramineclomipramine increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and clomipramine both increase QTc interval. Use Caution/Monitor.clozapineatomoxetine and clozapine both increase QTc interval. Use Caution/Monitor.darifenacindarifenacin will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.dasatinibatomoxetine and dasatinib both increase QTc interval. Use Caution/Monitor.degarelixatomoxetine and degarelix both increase QTc interval. Use Caution/Monitor.desipramineatomoxetine and desipramine both increase QTc interval. Use Caution/Monitor.desvenlafaxinedesvenlafaxine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mgdeutetrabenazineatomoxetine and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).diphenhydraminediphenhydramine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.dobutamineatomoxetine, dobutamine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously with vasopressors such as dobutamine.dolasetronatomoxetine and dolasetron both increase QTc interval. Use Caution/Monitor.donepezildonepezil and atomoxetine both increase QTc interval. Use Caution/Monitor.dopamineatomoxetine, dopamine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously with vasopressors such as dopamine.doxepindoxepin and atomoxetine both increase QTc interval. Use Caution/Monitor.dronedaronedronedarone will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.duloxetineduloxetine increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.efavirenzefavirenz and atomoxetine both increase QTc interval. Use Caution/Monitor.eliglustateliglustat increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.atomoxetine and eliglustat both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.ephedrineatomoxetine, ephedrine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously.epinephrineatomoxetine, epinephrine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously with vasopressors such as epinephrine.epinephrine inhaledatomoxetine, epinephrine inhaled. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.escitalopramescitalopram increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and escitalopram both increase QTc interval. Use Caution/Monitor.esketamine intranasalesketamine intranasal, atomoxetine. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Closely monitor blood pressure with concomitant use of esketamine nasal with stimulants. .fedratinibfedratinib will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.fingolimodfingolimod and atomoxetine both increase QTc interval. Use Caution/Monitor.fluconazoleatomoxetine and fluconazole both increase QTc interval. Use Caution/Monitor.fluoxetinefluoxetine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.fluphenazineatomoxetine and fluphenazine both increase QTc interval. Use Caution/Monitor.formoterolformoterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .atomoxetine and formoterol both increase QTc interval. Use Caution/Monitor.fostemsaviratomoxetine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. gemifloxacinatomoxetine and gemifloxacin both increase QTc interval. Use Caution/Monitor.gemtuzumabatomoxetine and gemtuzumab both increase QTc interval. Use Caution/Monitor.gilteritinibatomoxetine and gilteritinib both increase QTc interval. Use Caution/Monitor.goserelinatomoxetine and goserelin both increase QTc interval. Use Caution/Monitor.granisetronatomoxetine and granisetron both increase QTc interval. Use Caution/Monitor.haloperidolhaloperidol will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and haloperidol both increase QTc interval. Use Caution/Monitor.histrelinatomoxetine and histrelin both increase QTc interval. Use Caution/Monitor.hydroxyzineatomoxetine and hydroxyzine both increase QTc interval. Use Caution/Monitor.imatinibimatinib will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.indacaterol, inhaledatomoxetine and indacaterol, inhaled both increase QTc interval. Use Caution/Monitor.itraconazoleatomoxetine and itraconazole both increase QTc interval. Use Caution/Monitor.lapatinibatomoxetine and lapatinib both increase QTc interval. Use Caution/Monitor.leuprolideatomoxetine and leuprolide both increase QTc interval. Use Caution/Monitor.levalbuterollevalbuterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .atomoxetine and levalbuterol both increase QTc interval. Use Caution/Monitor.levofloxacinatomoxetine and levofloxacin both increase QTc interval. Use Caution/Monitor.lithiumatomoxetine and lithium both increase QTc interval. Use Caution/Monitor.lofexidineatomoxetine and lofexidine both increase QTc interval. Use Caution/Monitor.loperamideatomoxetine and loperamide both increase QTc interval. Use Caution/Monitor.lorcaserinlorcaserin will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lumefantrinelumefantrine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lurasidonelurasidone, atomoxetine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilineatomoxetine and maprotiline both increase QTc interval. Use Caution/Monitor.maravirocmaraviroc will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.mefloquineatomoxetine and mefloquine both increase QTc interval. Use Caution/Monitor.metaproterenolmetaproterenol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .methylphenidatemethylphenidate will increase the level or effect of atomoxetine by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode.midodrineatomoxetine, midodrine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously with vasopressors such as midodrine.mifepristoneatomoxetine and mifepristone both increase QTc interval. Use Caution/Monitor.mirabegronmirabegron will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.mirtazapineatomoxetine and mirtazapine both decrease QTc interval. Use Caution/Monitor.nilotinibnilotinib will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.norepinephrineatomoxetine, norepinephrine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously with vasopressors such as norepinephrine.nortriptylineatomoxetine and nortriptyline both increase QTc interval. Use Caution/Monitor.octreotideatomoxetine and octreotide both increase QTc interval. Use Caution/Monitor.ofloxacinatomoxetine and ofloxacin both increase QTc interval. Use Caution/Monitor.olanzapineatomoxetine and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instancesolodaterol inhaledatomoxetine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor.osilodrostatosilodrostat and atomoxetine both increase QTc interval. Use Caution/Monitor.panobinostatpanobinostat will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Panobinostat can increase the levels and effects of sensitive CYP2D6 substrates or those with a narrow therapeutic index CYP2D6.paroxetineparoxetine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.pasireotideatomoxetine and pasireotide both increase QTc interval. Use Caution/Monitor.peginterferon alfa 2bpeginterferon alfa 2b, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.perphenazineperphenazine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and perphenazine both increase QTc interval. Use Caution/Monitor.phenylephrineatomoxetine, phenylephrine. Other (see comment). Use Caution/Monitor. Comment: Due to the potential for increases in blood pressure and heart rate, atomoxetine should be used cautiously with vasopressors such as phenylephrine.pirbuterolpirbuterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .posaconazoleatomoxetine and posaconazole both increase QTc interval. Use Caution/Monitor.primaquineatomoxetine and primaquine both increase QTc interval. Use Caution/Monitor.propafenonepropafenone will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.protriptylineatomoxetine and protriptyline both increase QTc interval. Use Caution/Monitor.quinidinequinidine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.ranolazineranolazine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and ranolazine both increase QTc interval. Use Caution/Monitor.rilpivirineatomoxetine and rilpivirine both increase QTc interval. Use Caution/Monitor.risperidoneatomoxetine and risperidone both increase QTc interval. Use Caution/Monitor.ritonavirritonavir will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.rolapitantrolapitant will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.romidepsinatomoxetine and romidepsin both increase QTc interval. Use Caution/Monitor.salmeterolsalmeterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .sertralinesertraline will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.atomoxetine and sertraline both increase QTc interval. Use Caution/Monitor.solifenacinatomoxetine and solifenacin both increase QTc interval. Use Caution/Monitor.sunitinibatomoxetine and sunitinib both increase QTc interval. Use Caution/Monitor.tacrolimusatomoxetine and tacrolimus both increase QTc interval. Use Caution/Monitor.telavancinatomoxetine and telavancin both increase QTc interval. Use Caution/Monitor.terbinafineterbinafine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.terbutalineterbutaline, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .thioridazinethioridazine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.tipranavirtipranavir will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.triclabendazoleatomoxetine and triclabendazole both increase QTc interval. Use Caution/Monitor.trimipramineatomoxetine and trimipramine both increase QTc interval. Use Caution/Monitor.triptorelinatomoxetine and triptorelin both increase QTc interval. Use Caution/Monitor.valbenazinevalbenazine and atomoxetine both increase QTc interval. Use Caution/Monitor.vardenafilatomoxetine and vardenafil both increase QTc interval. Use Caution/Monitor.venlafaxinevenlafaxine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.vilanterol/fluticasone furoate inhaledatomoxetine and vilanterol/fluticasone furoate inhaled both increase QTc interval. Use Caution/Monitor.voclosporinatomoxetine and voclosporin both increase QTc interval. Use Caution/Monitor.voriconazoleatomoxetine and voriconazole both increase QTc interval. Use Caution/Monitor.vorinostatatomoxetine and vorinostat both increase QTc interval. Use Caution/Monitor.Minor (0)abirateroneMonitor Closely (1)abiraterone increases levels of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Reduced initial doses of atomoxetine are recommended with strong CYP2D6 inhibitors.albuterolMonitor Closely (1)atomoxetine, albuterol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of tachycardia, increased blood pressure.alfuzosinMonitor Closely (1)atomoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.amiodaroneMonitor Closely (1)amiodarone will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)atomoxetine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideSerious - Use Alternative (1)atomoxetine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.amitriptylineMonitor Closely (1)atomoxetine and amitriptyline both increase QTc interval. Use Caution/Monitor.anagrelideMonitor Closely (1)atomoxetine and anagrelide both increase QTc interval. Use Caution/Monitor.apomorphineMonitor Closely (1)atomoxetine and apomorphine both increase QTc interval. Use Caution/Monitor.arformoterolMonitor Closely (2)arformoterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. . atomoxetine and arformoterol both increase QTc interval. Use Caution/Monitor.arsenic trioxideSerious - Use Alternative (1)atomoxetine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrineMonitor Closely (1)artemether/lumefantrine will increase the level or effect of atomoxetine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)atomoxetine and artemether/lumefantrine both increase QTc interval. Avoid or Use